COMPASS Pathways Aktie

3,16 EUR -0,18 EUR -5,39 %

07.05.2025

STU

3,74 USD +0,10 USD +2,75 %

07.05.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Div. Rendite0,00%

WKNA2QCDR

ISINUS20451W1018

SymbolCMPS

COMPASS Pathways Aktien News

Sortieren:Datum Meistgelesen

01.08.24GlobeNewswireCompass Pathways announces second quarter 2024 financial results and business highlights

26.06.24GlobeNewswireCompass Pathways appoints Lori Englebert as Chief Commercial Officer

08.05.24GlobeNewswireCompass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

WerbungCOMPASS Pathways-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

08.05.24GlobeNewswireCompass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

02.05.24GlobeNewswireCompass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treat

29.04.24GlobeNewswireCompass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for tre

28.03.24GlobeNewswireCompass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

29.02.24GlobeNewswireCompass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

16.01.24GlobeNewswireCompass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

05.01.24GlobeNewswireCompass Pathways and Greenbrook TMS enter into three-year research collaboration agreement

19.12.23GlobeNewswireCompass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

07.12.23GlobeNewswireCompass Pathways appoints Teri Loxam as Chief Financial Officer

06.12.23GlobeNewswireStudy results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

15.11.23GlobeNewswireCompass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

02.11.23GlobeNewswireCOMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

26.10.23GlobeNewswireCOMPASS Pathways announces CFO transition

18.09.23GlobeNewswireCOMPASS Pathways appoints Daphne Karydas to its Board of Directors

06.09.23GlobeNewswireCOMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

16.08.23GlobeNewswireCOMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

03.08.23GlobeNewswireCOMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

25.07.23GlobeNewswireFirst clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine

17.07.23GlobeNewswireCOMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmac

13.07.23GlobeNewswireOpinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin

06.07.23GlobeNewswireAmerican Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

31.05.23GlobeNewswireCOMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

26.05.23GlobeNewswireData Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

11.05.23GlobeNewswireCOMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

02.05.23GlobeNewswireAmerican Medical Association to Issue First New Code for Psychedelic Therapies

28.02.23GlobeNewswireCOMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

03.11.22GlobeNewswireCOMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

04.08.22GlobeNewswireCOMPASS Pathways plc announces second quarter 2022 financial results and business highlights

28.07.22GlobeNewswireCOMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

19.07.22GlobeNewswireCOMPASS Pathways appoints Kabir Nath as Chief Executive Officer

23.05.22GlobeNewswireCOMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting

10.05.22GlobeNewswireCOMPASS Pathways plc announces first quarter 2022 financial results and business highlights

09.05.22GlobeNewswireCOMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

COMPASS Pathways News

COMPASS Pathways News: auf dieser Seite finden Sie alle COMPASS Pathways News und Nachrichten zur COMPASS Pathways Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch COMPASS Pathways News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um COMPASS Pathways News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.